Search Results
May 14, 2026, 03:23 ET ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
May 14, 2026, 03:17 ET Hercules Capital, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HTGC
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
May 14, 2026, 03:13 ET Power Solutions International, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PSIX
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
May 14, 2026, 03:10 ET Gartner, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IT
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
May 14, 2026, 03:09 ET Gemini Space Station, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GEMI
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
May 14, 2026, 02:30 ET Artmarket.com: T1 2026 en hausse, Manifeste Artprice by Artmarket : 22 règles pour un Marché de l'Art régulé et transparent à l'ère de l'IA
d'Artmarket Insight, agence de presse mondiale spécialisée créé en 2001 en format hebdomadaire. Artprice News possède une couverture mondiale 24 h/24 et 7 j/7 dans 122 pays et 11 langues. Ce déploiement stratégique représente un changement de paradigme majeur : Artprice passe d'un calendrier hebdomadaire avec
More news about: Artmarket.com
May 13, 2026, 16:15 ET Nanalysis Announces First Quarter 2026 Conference Call
https://us02web.zoom.us/j/87624958529?pwd=FxTQ2xf1geEDJ3svrWXYSiNBZ7rJ5g.1Meeting ID: 876 2495 8529Passcode: 351966One tap mobile+16699006833,,87624958529#,,,,*351966#
More news about: Nanalysis Scientific Corp.
May 13, 2026, 16:05 ET Precigen Reports First Quarter 2026 Financial Results and Business Updates
therapy.Permanent J-code accelerating site activations and patient access: Effective April 1, 2026, the Centers for Medicare and Medicaid Services assigned a permanent J-code (J3404) to PAPZIMEOS, and early indicators suggest this is already streamlining site activations. J-codes are standardized
More news about: Precigen, Inc.
May 13, 2026, 16:05 ET MDJM LTD to Host Virtual Investor Meeting on May 15, 2026
https://us06web.zoom.us/j/87101151746?pwd=UO71grewBaO7g9FpiOB8IEhqjSTuM7.1Meeting ID: 871 0115 1746Passcode: 319270About MDJM LTDMDJM LTD is a global culture-driven
More news about: MDJM LTD
May 13, 2026, 16:00 ET CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
XU.S. Company Contact:Peter J. Mariani, Chief Financial Officer305 College Road EastPrinceton, NJ 08540
More news about: Cytosorbents Corp
May 13, 2026, 14:57 ET The Michael J. Fox Foundation Applauds Vermont, First State to Pass Ban on Parkinson's-Linked Pesticide Paraquat -- A Historic Step Forward and Call to Action Nationwide
bans and advance policies that protect public health.About The Michael J. Fox Foundation for Parkinson's Research (MJFF):As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and
More news about: The Michael J. Fox Foundation for Parkinson's Research
May 13, 2026, 14:14 ET Angioedema hereditário: uma iniciativa europeia para dar visibilidade a uma doença ainda pouco conhecida
https://onlinelibrary.wiley.com/doi/10.1111/all.15214[3] Zuraw 2010: Zuraw BL. The pathophysiology of hereditary angioedema. World Allergy Organ J. 2010 Sep;3(9 Suppl):S25-8. doi: 10.1097/WOX.0b013e3181f3f21c. PMID: 23282866; PMCID: PMC3666152.
More news about: BioCryst Ireland, a Neopharmed Gentili company
May 13, 2026, 12:59 ET SMIRNOFF ICE COUPLES UP WITH LOVE ISLAND USA TO TURN FAN VOTES INTO NEW FLAVORS
in beverage alcohol with an outstanding collection of brands across spirits and beer categories. These brands include Johnnie Walker, Crown Royal, J&B and Buchanan's whiskies, Smirnoff and Ketel One vodkas, Captain Morgan, Baileys, Don Julio, Tanqueray and Guinness.Diageo is a global company,
More news about: Smirnoff Ice
May 13, 2026, 11:39 ET Neurocritical Care Leaders to Discuss NPi Pupillometry in NeurOptics Sessions at AACN NTI 2026
NeurOptics.com.References Cho SM, Hwang J, Chiarini G, et al. Neurological monitoring and management for adult extracorporeal membrane oxygenation patients: Extracorporeal Life Support Organization
More news about: NeurOptics
May 13, 2026, 10:58 ET DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
pipeline drugs through clinical trials. Moreover, the deals recently finalized by management have yet to demonstrate meaningful results. The recent J&J deal for ZILRETTA has yielded disappointing results, as the brand experienced a decline in sales revenue in 2025 despite premium pricing that a patented
More news about: DOMA Perpetual
May 13, 2026, 10:45 ET Leidos to build initial 3,000 low-cost containerized munitions through Department of War framework agreement
Leidos (NYSE: LDOS) Low-Cost Containerized Munitions (LCCM) through a framework agreement with the Department of War that advances President Donald J. Trump and Secretary of War Pete Hegseth's "Arsenal of Freedom" initiative.
More news about: Leidos Holdings, Inc.
May 13, 2026, 09:41 ET Dziedziczny obrzęk naczynioruchowy: europejska inicjatywa na rzecz zwrócenia uwagi na to mało znane schorzenie
https://onlinelibrary.wiley.com/doi/10.1111/all.15214[3] Zuraw 2010: Zuraw BL. The pathophysiology of hereditary angioedema (Patofizjologia dziedzicznego obrzęku naczynioruchowego); World Allergy Organ J., wrzesień 2010; 3(9 Suppl):S25-8. doi: 10.1097/WOX.0b013e3181f3f21c. PMID: 23282866; PMCID: PMC3666152.
More news about: BioCryst Ireland, a Neopharmed Gentili company
May 13, 2026, 09:36 ET USA-IT Urges Congress to Crack Down on Growing Illegal Trade Threat Fueling Organized Crime
intelligence to keep pace with evolving threats."These are not isolated crimes—they are interconnected, global criminal systems," said Timothy J. Cruz, District Attorney of Plymouth County, Massachusetts, and President of the National District Attorneys Association. "Today's networks are agile,
More news about: USA-IT
May 13, 2026, 09:04 ET UnqorkAI Ends the Chaos of Enterprise AI Code Sprawl
Samuel J. "Sam" Palmisano, former IBM CEO and Chairman, who recently joined Unqork's Board of Advisors.Key BenefitsBuild
More news about: Unqork
May 13, 2026, 09:02 ET J. Lohr Vineyards & Wines Celebrates 25 Years of Hospitality at Its Paso Robles Wine Center
styles that showcase its estate fruit, J. Lohr crafts eight tiers of award-winning wines: J. Lohr Signature Cabernet Sauvignon, J. Lohr Cuvée Series, J. Lohr Vineyard Series, J. Lohr Gesture, J. Lohr Pure Paso® Proprietary Red Wine, J. Lohr Estates, J. Lohr Monterey Roots, and ARIEL Vineyards.
More news about: J. Lohr Vineyards & Wines
May 13, 2026, 09:00 ET Stimvia Expands Scientific Advisory Board and Commercial Leadership to Advance Global Market Expansion of Flagship URIS® Therapy
in lower urinary tract functional disorders, with extensive experience in medical device development and clinical investigation;Prof. Alan J. Wein, MD, PhD (Hon), FACS, a leading authority in OAB and contributor to international treatment guidelines, formerly Chief of Urology at the University
More news about: STIMVIA
May 13, 2026, 09:00 ET Stimvia Expands Scientific Advisory Board and Commercial Leadership to Advance Global Market Expansion of Flagship URIS® Therapy
in lower urinary tract functional disorders, with extensive experience in medical device development and clinical investigation;Prof. Alan J. Wein, MD, PhD (Hon), FACS, a leading authority in OAB and contributor to international treatment guidelines, formerly Chief of Urology at the University
More news about: STIMVIA
May 13, 2026, 09:00 ET Stimvia erweitert den wissenschaftlichen Beirat und die kommerzielle Führung, um die globale Marktexpansion der Flaggschiff-Therapie URIS® voranzutreiben
Funktionsstörungen des unteren Harntrakts, mit umfangreicher Erfahrung in der Entwicklung von Medizinprodukten und klinischen Untersuchungen;Prof. Alan J. Wein, MD, PhD (Hon), FACS, eine führende Autorität auf dem Gebiet der OAB und Mitwirkender an internationalen Behandlungsrichtlinien, früher Chefarzt
More news about: STIMVIA
May 13, 2026, 09:00 ET Stimvia élargit son conseil scientifique et son leadership commercial afin d'accélérer l'expansion de sa thérapie phare URIS® sur le marché mondial.
des voies urinaires inférieures, possédant une vaste expérience dans le développement de dispositifs médicaux et les études cliniques ;Alan J. Wein, MD, PhD (Hon), FACS, une autorité de premier plan dans le domaine de l'hyperactivité vésicale et un contributeur aux lignes directrices internationales
More news about: STIMVIA
May 13, 2026, 09:00 ET Stimvia impulsará la expansión global de su terapia insignia URIS®
funcionales del tracto urinario inferior, con amplia experiencia en el desarrollo de dispositivos médicos e investigación clínica;Profesor Alan J. Wein, MD, PhD (Hon), FACS, una autoridad destacada en vejiga hiperactiva y colaborador en guías de tratamiento internacionales, anteriormente Jefe
More news about: STIMVIA